These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 39459978)
21. The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection. Lécuyer D; Nardacci R; Tannous D; Gutierrez-Mateyron E; Deva Nathan A; Subra F; Di Primio C; Quaranta P; Petit V; Richetta C; Mostefa-Kara A; Del Nonno F; Falasca L; Marlin R; Maisonnasse P; Delahousse J; Pascaud J; Deprez E; Naigeon M; Chaput N; Paci A; Saada V; Ghez D; Mariette X; Costa M; Pistello M; Allouch A; Delelis O; Piacentini M; Le Grand R; Perfettini JL Front Immunol; 2023; 14():1270081. PubMed ID: 37920468 [TBL] [Abstract][Full Text] [Related]
22. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein. Yalcinkaya M; Liu W; Islam MN; Kotini AG; Gusarova GA; Fidler TP; Papapetrou EP; Bhattacharya J; Wang N; Tall AR Sci Rep; 2021 Dec; 11(1):24432. PubMed ID: 34952919 [TBL] [Abstract][Full Text] [Related]
23. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Zhao N; Di B; Xu LL Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243 [TBL] [Abstract][Full Text] [Related]
24. Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention. Zhang J; Ma X; Liu F; Zhang D; Ling J; Zhu Z; Chen Y; Yang P; Yang Y; Liu X; Zhang J; Liu J; Yu P Front Immunol; 2023; 14():1203389. PubMed ID: 37868953 [TBL] [Abstract][Full Text] [Related]
25. Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors. Diarimalala RO; Wei Y; Hu D; Hu K Front Cell Infect Microbiol; 2023; 13():1218039. PubMed ID: 37360532 [TBL] [Abstract][Full Text] [Related]
26. NLRP3 inflammasome-induced pyroptosis and serum ASC specks are increased in patients with cardiogenic shock. Kogel A; Baumann L; Maeder C; Büttner P; Thiele H; Kneuer JM; Boeckel JN; Laufs U; Gaul S Am J Physiol Heart Circ Physiol; 2024 Oct; 327(4):H869-H879. PubMed ID: 39178030 [TBL] [Abstract][Full Text] [Related]
28. Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination. Lee SK; Kwon JH; Yoon N; Lee SH; Sung PS J Hepatol; 2022 Oct; 77(4):1209-1211. PubMed ID: 35817223 [No Abstract] [Full Text] [Related]
29. Targeting the NLRP3 Inflammasome in Severe COVID-19. Freeman TL; Swartz TH Front Immunol; 2020; 11():1518. PubMed ID: 32655582 [TBL] [Abstract][Full Text] [Related]
30. Apoptosis-associated speck-like protein containing a CARD forms specks but does not activate caspase-1 in the absence of NLRP3 during macrophage swelling. Compan V; Martín-Sánchez F; Baroja-Mazo A; López-Castejón G; Gomez AI; Verkhratsky A; Brough D; Pelegrín P J Immunol; 2015 Feb; 194(3):1261-73. PubMed ID: 25552542 [TBL] [Abstract][Full Text] [Related]
31. ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities. Zheng R; Yan Y; Dai S; Ruan Y; Chen Y; Hu C; Lin Z; Xue N; Song Z; Liu Y; Zhang B; Pu J J Neuroinflammation; 2023 Feb; 20(1):26. PubMed ID: 36740674 [TBL] [Abstract][Full Text] [Related]
32. Persistent Oxidative Stress and Inflammasome Activation in CD14 Lage SL; Amaral EP; Hilligan KL; Laidlaw E; Rupert A; Namasivayan S; Rocco J; Galindo F; Kellogg A; Kumar P; Poon R; Wortmann GW; Shannon JP; Hickman HD; Lisco A; Manion M; Sher A; Sereti I Front Immunol; 2021; 12():799558. PubMed ID: 35095880 [TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Pan P; Shen M; Yu Z; Ge W; Chen K; Tian M; Xiao F; Wang Z; Wang J; Jia Y; Wang W; Wan P; Zhang J; Chen W; Lei Z; Chen X; Luo Z; Zhang Q; Xu M; Li G; Li Y; Wu J Nat Commun; 2021 Aug; 12(1):4664. PubMed ID: 34341353 [TBL] [Abstract][Full Text] [Related]
34. Detection of Cui J; Oehrl S; Ahmad F; Brenner T; Uhle F; Nusshag C; Rupp C; Funck F; Meisel S; Weigand MA; Morath C; Schäkel K Front Immunol; 2020; 11():613745. PubMed ID: 33613537 [TBL] [Abstract][Full Text] [Related]
35. Galectin-3 regulates inflammasome activation in cholestatic liver injury. Tian J; Yang G; Chen HY; Hsu DK; Tomilov A; Olson KA; Dehnad A; Fish SR; Cortopassi G; Zhao B; Liu FT; Gershwin ME; Török NJ; Jiang JX FASEB J; 2016 Dec; 30(12):4202-4213. PubMed ID: 27630169 [TBL] [Abstract][Full Text] [Related]
36. Autoimmune hepatitis and primary biliary cholangitis overlap syndrome after COVID-19. Cunha-Silva M; de França EVC; Greca RD; Mazo DFC; da Costa LBE; de Moraes PBS; Veiga CT; Assis-Mendonça GR; Boin IFSF; Stucchi RSB; Sevá-Pereira T Autops Case Rep; 2023; 13():e2023422. PubMed ID: 37034275 [TBL] [Abstract][Full Text] [Related]
37. Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats. Nagaraja S; Jain D; Kesavardhana S J Leukoc Biol; 2022 Feb; 111(2):497-508. PubMed ID: 34057760 [TBL] [Abstract][Full Text] [Related]
38. Autoimmune sclerosing cholangitis might be triggered by SARS-CoV-2 infection in a child - a case report. Zdanowicz K; Bobrus-Chociej A; Kopiczko A; Uścinowicz M; Tomczuk-Ostapczuk M; Janica J; Łotowska JM; Białokoz-Kalinowska I; Lebensztejn DM Cent Eur J Immunol; 2022; 47(2):183-187. PubMed ID: 36751389 [TBL] [Abstract][Full Text] [Related]
39. Lung Inflammasome Activation in SARS-CoV-2 Post-Mortem Biopsies. Baena Carstens L; Campos D'amico R; Fernandes de Moura K; Morais de Castro E; Centenaro F; Silva Barbosa G; Vieira Cavalcante da Silva G; Brenny I; Honório D'Agostini JC; Hlatchuk EC; Pissette de Lima S; Camargo Martins AP; De Castro Deus M; Konzen Klein C; Kubaski Benevides AP; Nagashima S; Machado-Souza C; Pinho RA; Pellegrino Baena C; de Noronha L Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361818 [TBL] [Abstract][Full Text] [Related]